The experimental drug donanemab slowed the progression of Alzheimer's disease by about 35% in a study of more than 1,700 people. Eli Lilly, the company that makes the drug, has submitted the results of its study to the Food and Drug Administration, which is expected to make a decision on the drug by the end of the year. The drug is still not a cure - its benefits amount to only about a seven-month delay in the loss of memory and thinking. The drug caused dangerous swelling or bleeding in the brain in about 25% of patients.